April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Intravitreal Injection of Bevacizumab Vs. Conventional Laser Treatment in Type 1 ROP
Fernando Molle; Domenico Lepore; Antonio Baldascino; Carmine Angora; Lorenzo Orazi; Monica M. Pagliara; Carmen Giannantonio; Velia Purcaro; Patrizia Papacci; Costantino Romagnoli
Author Affiliations & Notes
  • Fernando Molle
    Department of Ophthalmology,
    Catholic University, Rome, Italy
  • Domenico Lepore
    Department of Ophthalmology,
    Catholic University, Rome, Italy
  • Antonio Baldascino
    Department of Ophthalmology,
    Catholic University, Rome, Italy
  • Carmine Angora
    Department of Ophthalmology,
    Catholic University, Rome, Italy
  • Lorenzo Orazi
    Department of Ophthalmology,
    Catholic University, Rome, Italy
  • Monica M. Pagliara
    Department of Ophthalmology,
    Catholic University, Rome, Italy
  • Carmen Giannantonio
    Department of Pediatrics,
    Catholic University, Rome, Italy
  • Velia Purcaro
    Department of Pediatrics,
    Catholic University, Rome, Italy
  • Patrizia Papacci
    Department of Pediatrics,
    Catholic University, Rome, Italy
  • Costantino Romagnoli
    Department of Pediatrics,
    Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships  Fernando Molle, None; Domenico Lepore, None; Antonio Baldascino, None; Carmine Angora, None; Lorenzo Orazi, None; Monica M. Pagliara, None; Carmen Giannantonio, None; Velia Purcaro, None; Patrizia Papacci, None; Costantino Romagnoli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3143. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Intravitreal Injection of Bevacizumab Vs. Conventional Laser Treatment in Type 1 ROP
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Fernando Molle, Domenico Lepore, Antonio Baldascino, Carmine Angora, Lorenzo Orazi, Monica M. Pagliara, Carmen Giannantonio, Velia Purcaro, Patrizia Papacci, Costantino Romagnoli; Intravitreal Injection of Bevacizumab Vs. Conventional Laser Treatment in Type 1 ROP. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3143.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : to evaluate structural outcome of Intravitreal injection of Bevacizumab (IVB) for type I ROP compared to conventional laser treatment.

Methods: : monocentric Randomized controlled trial started September 1st ‘09 at Neonatal Intensive Care Unit (NICU) of the Catholic University in Rome. All inborn babies with type 1 zone 1 ROP and therefore eligible for laser photoablation following the ETROP indications were included in the study. Until 31st July ’10 7 babies (14 eyes) with a mean BW of 606.7gr (range 450-840) and a mean GA of 25.8wks (range 23-29) were enorolled. At the time of treatment the first eye was randomized for intravitreal injection of 0.5mg di Avastin in a 0.02 ml BS solution; the second eye, used as control, was randomized for conventional laser photoablation of the peripheral avascular retina. Binocular indirect ophthalmoscopy (BIO) and digital Retcam were performed before treatment and every 3 days while digital FA at treatment and every 2 wks until discharge. After discharge from NICU, BIO was performed every 2 wks until 52nd wk of PMA and then monthly until 1 years of age. Babies underwent FA, cyclopegic refraction and IOP measurement at 6 month and at 1 year of age under general anaesthesia.

Results: : one eye of the laser group progressed to stage 4b and therefore results considered unfavourable according to CryoROP. Remaining 6 eyes showed positive results. None of the eyes treatment with a single IVB progressed to retinal detachment but showed an incomplete vascularisation of the peripheral retina. Furthermore all but one eyes showed some fluorangiographic abnormalities either at the periphery or at the posterior pole.

Conclusions: : the IVB seems to be able to stop the progression to retinal detachment. Some concerns for the use of IVB in type 1 zone 1 arise from the FA study. Long term follow-up is needed to evaluate the effect of bevacizumab on panretinal development.

Clinical Trial: : https://eudract.ema.europa.eu 2009-012609-20

Keywords: retinopathy of prematurity • vascular endothelial growth factor • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept